 |
Articles: Myeloproliferative Dz |
Prior Articles
Infections in Patients With Multiple Myeloma
Seminars in Hematology, 07/27/09
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
British Journal of Haematology, 07/21/09 Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease - implications for clinical trial design and enrollment
Blood, 07/21/09 Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
Journal of Clinical Oncology, 07/20/09 Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A southwest oncology group trial (S0204)
Journal of Clinical Oncology, 07/20/09 The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review
Cancer Treatment Reviews, 07/20/09 Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
Annals of Oncology, 07/17/09 Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
Annals of Oncology, 07/17/09 5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics
Oncogene, 07/16/09 Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms
Cancer Epidemiology, Biomarkers & Prevention, 07/15/09 Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows
Leukemia Research, 07/13/09 p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
Leukemia Research, 07/13/09 The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome
Leukemia Research, 07/13/09 Azacitidine for the treatment of myelodysplastic syndrome
Expert Review of Anticancer Therapy, 07/13/09 Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma
Expert Review of Anticancer Therapy, 07/13/09 NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes
British Journal of Haematology, 07/09/09
Exclusive Author Commentary The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes
Cancer, 07/07/09 Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Blood, 07/02/09 Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996)
Blood, 07/02/09 Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
Blood, 07/02/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
188 Available Pages
|
|
